# NFX Bio

> NFX Bio is a VC fund in San Francisco backing Therapeutics and Biotechnology. See 5 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: San Francisco, United States
- Total investments: 5
- Last investment: May 2024
- Lead investor: 60%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/nfxvc
- Website: https://www.nfx.com/bio/

NFX Bio is a fund initiative that seeks to invest in scientist-founders at the seed stage with a technology platform approach.Led by Omri Amirav Drory, a venture partner with NFX, who founded Genome Compiler, it helps scientists learn to be founders and guides biology companies with information technology to be a critical distinction with massiveimplications.

## Contacts

5 contacts available for NFX Bio. Shizune tracks 5 team members at NFX Bio. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/nfx-bio?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $7M–$22M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Therapeutics | 4 | 80% |
| Biotechnology | 3 | 60% |
| Medical | 2 | 40% |
| Health Care | 2 | 40% |
| Genetics | 1 | 20% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 4 | 80% |
| Series B | 1 | 20% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 3 | 60% |
| Israel | 2 | 40% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Emily Leproust | Investment Committee | 3 | https://shizune.co/investors/profile/dr-emily-leproust |
| Gigi Levy Weiss | Investment Committee | 129 | https://shizune.co/investors/profile/gigi-levy-weiss |
| Gita Reinitz | Principal | 0 | https://shizune.co/investors/profile/gita-reinitz |
| James Currier | Investment Committee | 84 | https://shizune.co/investors/profile/james-currier |
| Omri Amirav-Drory | Venture Partner | 16 | https://shizune.co/investors/profile/omri-amirav-drory |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Radar Therapeutics | Radar Therapeutics pioneer in treatment modality, precision-expressed mRNA-based therapeutics. | $13.4M | Seed | May 23, 2024 |  |
| Eleven Therapeutics | Eleven Therapeutics is a research firm that unleashes the power of RNAi technology that helps to create precise and durable therapeutics. | $22M | Seed | Aug 02, 2022 |  |
| resistanceBio | Solving cancer resistance. | $12M | Seed | Jul 04, 2022 |  |
| Pangea Therapeutics Ltd. | Pangea provides services to Pharma/Biotech companies based on its proprietary platform. | $7M | Seed | Jul 07, 2021 |  |
| C2i Genomics | C2i Genomics provides cloud-based cancer diagnostic services to pharmaceutical and diagnostic organizations.The cancer intelligence company is developing a platform that can perform whole-genome sequencing using only 2 milliliters of blood. Its ultra-sensitive liquid biopsy assay allows physicians to monitor patient treatment response and detecttreatment failure or disease recurrence months and potentially years earlier than current monitoring methods. C2i’s cancer diagnostics service uses artificial intelligence pattern recognition and the whole-genome analysis to spot trace amounts of cancer much quicker, in about a week, to inform better treatment decisions and ultimately save lives. The company aims to help patients avoid unnecessary overtreatment with toxic chemotherapy or radiation, as well as to prevent them from going without treatment while cancer quietly grows and metastasizes.In 2019, Boris Oklander, Asaf Zviran, and Ezra Sofer established the company in New York, New York. | $100M | Series B | Apr 15, 2021 |  |

5 of 5 investments shown.

## Co-investors
- [Casdin Capital](https://shizune.co/investors/profile/casdin-capital) — VC Fund, 2 deals together
- [Pioneer Fund](https://shizune.co/investors/profile/pioneer-fund) — VC Fund, 2 deals together
- [Alexandria Real Estate Equities](https://shizune.co/investors/profile/alexandria-real-estate-equities) — VC Fund, 1 deal together
- [BEVC](https://shizune.co/investors/profile/bevc) — VC Fund, 1 deal together
- [Bill & Melinda Gates Foundation](https://shizune.co/investors/profile/bill-melinda-gates-foundation) — VC Fund, 1 deal together
- [Biovision Ventures](https://shizune.co/investors/profile/biovision-ventures) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [F6 Ventures](https://shizune.co/investors/profile/flat6labs) — VC Fund
- [Oqal](https://shizune.co/investors/profile/oqal) — VC Fund
- [Alesta Yatırım](https://shizune.co/investors/profile/alesta-girisim) — VC Fund

## Featured in investor lists
- [Biotechnology Investors in Middle East](https://shizune.co/investors/biotechnology-investors-middle-east)
- [Biotechnology VC Funds in Middle East](https://shizune.co/investors/biotechnology-vc-funds-middle-east)
- [Biotech Investors in Middle East](https://shizune.co/investors/biotech-investors-middle-east)
- [Biotech VC Funds in Middle East](https://shizune.co/investors/biotech-vc-funds-middle-east)
- [Biotech Investors in Israel](https://shizune.co/investors/biotech-investors-israel)
- [Biotech VC Funds in Israel](https://shizune.co/investors/biotech-vc-funds-israel)

## FAQ

### What does NFX Bio invest in?

NFX Bio invests primarily in Therapeutics, Biotechnology and Medical startups, most often at Seed and Series B stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is NFX Bio's check size?

NFX Bio typically joins rounds of $7M–$22M at Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds NFX Bio participates in.

### How do I contact NFX Bio?

Public channels for NFX Bio include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at NFX Bio?

The team at NFX Bio includes Emily Leproust (Investment Committee), Gigi Levy Weiss (Investment Committee) and Gita Reinitz (Principal). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co